Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions
Authors
Keywords
-
Journal
Small
Volume 11, Issue 31, Pages 3755-3761
Publisher
Wiley
Online
2015-04-28
DOI
10.1002/smll.201500324
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive studies of pharmacokinetics and biodistribution of indocyanine green and liposomal indocyanine green by multispectral optoacoustic tomography
- (2015) Wantong Song et al. RSC Advances
- Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
- (2014) Edward A. Sykes et al. ACS Nano
- Integration of Nanoassembly Functions for an Effective Delivery Cascade for Cancer Drugs
- (2014) Qihang Sun et al. ADVANCED MATERIALS
- A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections
- (2014) Peng Liu et al. ANTI-CANCER DRUGS
- PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment
- (2014) Hecheng Ma et al. BIOMATERIALS
- A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
- (2014) F A L M Eskens et al. BRITISH JOURNAL OF CANCER
- EPR: Evidence and fallacy
- (2014) Joseph W. Nichols et al. JOURNAL OF CONTROLLED RELEASE
- Co-Delivery of Doxorubicin and siRNA with Reduction and pH Dually Sensitive Nanocarrier for Synergistic Cancer Therapy
- (2014) Weicai Chen et al. Small
- Tumor Vasculature Targeting: A Generally Applicable Approach for Functionalized Nanomaterials
- (2014) Feng Chen et al. Small
- Parkin regulates kainate receptors by interacting with the GluK2 subunit
- (2014) AnnaMaria Maraschi et al. Nature Communications
- Facing the Truth about Nanotechnology in Drug Delivery
- (2013) Kinam Park ACS Nano
- Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
- (2013) C. Sessa et al. CLINICAL CANCER RESEARCH
- Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice
- (2013) Darren Lars Stirland et al. JOURNAL OF CONTROLLED RELEASE
- A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
- (2013) Anna K. Nowak et al. LUNG CANCER
- Nanoparticle Delivered Vascular Disrupting Agents (VDAs): Use of TNF-Alpha Conjugated Gold Nanoparticles for Multimodal Cancer Therapy
- (2013) Mithun M. Shenoi et al. MOLECULAR PHARMACEUTICS
- Superior Penetration and Retention Behavior of 50 nm Gold Nanoparticles in Tumors
- (2012) S. Huo et al. CANCER RESEARCH
- Fast Multispectral Optoacoustic Tomography (MSOT) for Dynamic Imaging of Pharmacokinetics and Biodistribution in Multiple Organs
- (2012) Adrian Taruttis et al. PLoS One
- Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
- (2011) M. Zweifel et al. ANNALS OF ONCOLOGY
- Targeted drug delivery to tumors: Myths, reality and possibility
- (2011) You Han Bae et al. JOURNAL OF CONTROLLED RELEASE
- The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
- (2010) Michelle Head et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles
- (2010) Helen Lee et al. MOLECULAR PHARMACEUTICS
- Preclinical and clinical studies of anticancer agent-incorporating polymer micelles
- (2009) Yasuhiro Matsumura et al. CANCER SCIENCE
- A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
- (2009) Dietmar W Siemann et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
- (2009) Steven D. Perrault et al. NANO LETTERS
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
- (2008) Patricia M. LoRusso et al. INVESTIGATIONAL NEW DRUGS
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation